Delcath Systems Inc (DCTH) is a publicly traded Healthcare sector company. As of May 21, 2026, DCTH trades at $11.23 with a market cap of $382.85M and a P/E ratio of 561.10. DCTH moved +3.41% today. Year to date, DCTH is +9.45%; over the trailing twelve months it is -37.51%. Its 52-week range spans $8.08 to $18.23. Analyst consensus is strong buy with an average price target of $25.25. Rallies surfaces DCTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Analyst Increases Delcath Systems Price Target to $29 After Q4 Revenue of $20.7M: An analyst raised Delcath Systems' price target to $29 from $28 while maintaining a Buy rating following preliminary Q4 results. The company reported preliminary Q4 revenue of $20.7 million and full-year 2025 revenue of $85.2 million, led by Hepzato sales totaling $19.0 million for the quarter and $78.8 million for the year.
| Metric | Value |
|---|---|
| Price | $11.23 |
| Market Cap | $382.85M |
| P/E Ratio | 561.10 |
| EPS | $0.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.23 |
| 52-Week Low | $8.08 |
| Volume | 1.55K |
| Avg Volume | 0 |
| Revenue (TTM) | $90.44M |
| Net Income | $561.00K |
| Gross Margin | 85.97% |
5 analysts cover DCTH: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.25.